Chimerix (NASDAQ: CMRX) reported Q2 EPS of ($0.59), in-line with the analyst estimate of ($0.59). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $1.37 million.

M. Michelle Berrey, MD, MPH, President and CEO, said, "We are very pleased with the key milestones that we have achieved for brincidofovir and the company. We recently reported a statistically significant survival benefit for brincidofovir in a pivotal study in an animal model of smallpox, an important step toward a potential FDA approval of brincidofovir as the first antiviral treatment for smallpox. We completed our target enrollment for both clinical Phase 3 SUPPRESS and AdVise trials, and strengthened our financial position by completing an offering of common stock. The transplant community is increasingly recognizing the frequency of serious viral infections and in particular the cumulative impact of these viral infections on the twenty percent non-relapse mortality in allogeneic HCT. We are diligently preparing for availability of data from SUPPRESS and AdVise in early 2016 and, if positive, the brincidofovir NDA and MAA to follow."

For earnings history and earnings-related data on Chimerix (CMRX) click here.